Research Paper Volume 13, Issue 21 pp 24155—24170
Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma
Figure 4. The roles of the immune signature in evaluating ICI treatment efficacy for advanced urothelial cancer (UC). (A) Kaplan-Meier survival plots of low-risk versus high-risk subgroups in the anti-PD-L1-treated UC cohort. (B) Forest plot of the multivariate Cox regression models with sex, ECOG score, smoking status, and immune phenotype taken into account to exhibit the association of the identified immune signature with ICI survival. (C) The proportion of therapeutic advantages to anti-PD-L1 therapy in low versus high-risk OS subgroups. (D) Distribution of immune signature risk scores in patients with distinct ICI treatment effect. (E) Tumor mutation burden and (F) neoantigen burden distribution in low-risk versus high-risk OS subgroups with the genomic data from UC immunotherapy cohort.